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ABSTRACT 
 
L-ascorbic acid (AA), commonly known as vitamin C, has been widely used in topical 
formulations for many years as an antioxidant and anti-aging ingredient. However, the 
physicochemical properties of AA are not optimal for skin uptake and the molecule is also 
unstable, readily undergoing oxidation on exposure to air. The compound 3-o-ethyl-l-ascorbic 
acid (EA) has been developed as a stable vitamin C derivative and has been used in topical 
products. The aims of this work were to conduct a comprehensive characterisation of 
physicochemical properties of EA as well as to investigate the influence of various neat solvents 
on EA skin delivery. Nuclear magnetic resonance (NMR), mass spectroscopy, differential 
scanning calorimetry (DSC) and thermogravimetric analysis (TGA) were used to characterise the 
molecule. The pKa of the compound and the partition coefficient logP(o/w) were experimentally 
determined. A new HPLC method for analysis of the molecule was also developed and validated. 
A number of solvents for topical preparations were selected based on their wide use as excipients 
in topical formulations, their potential to act as skin penetration enhancers and their favourable 
safety profiles. The solubility and stability of EA was examined. Skin permeation of the molecule 
in full thickness porcine skin in vitro was investigated using Franz-type diffusion cells. The 
melting point, log P(o/w) value and pKa value of EA were determined to be 114.39 ± 0.5
o C, -1.07 
± 0.03 and 7.72 ± 0.01 respectively. Skin penetration of EA was evident for the following 
vehicles 1,2 hexanediol (HEX), glycerol (GLY), propylene glycol (PG), 1,2 pentanediol (1-2P), 
isopropyl alcohol (IPA), propylene glycol monolaurate (PGML) and propylene glycol 
monocaprylate (PGMC). Skin uptake but no permeation through the skin was observed for 
Transcutol® (TC) and dipropylene glycol (DiPG), while no penetration was observed for the 
solvents 1,5 pentanediol (1-5P) and tripropylene glycol (TriPG). The findings of the permeation 
experiments confirm the potential of simple formulations to deliver EA to the skin. Studies are 
ongoing to identify complex vehicles for synergistic enhancement of EA skin penetration. To our 
knowledge this is the first study to conduct a comprehensive characterization of EA and examine 
its skin uptake and permeation properties in porcine skin. 
 
Key words: In vitro, porcine skin, permeation, finite dose, 3-o-ethyl ascorbic acid 
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1. Introduction 
 
L-ascorbic acid (AA), or vitamin C, is a water-soluble antioxidant that has been used 
in personal care formulations for many years. A number of studies in cultured cells have been 
used to explore the mechanism of action of AA in vitro. The molecule was shown to protect 
cells against UV-induced oxidative damage by scavenging free radicals and reactive oxygen 
species (Colven and Pinnell 1996; Chan 1993). AA has also been shown to stimulate collagen 
synthesis in human dermal fibroblasts, being co-factor for the formation of hydroxyproline 
and hydroxylysine (Boyera, Galey, and Bernard 1998; Kameyama et al. 1996; Pielesz et al. 
2017; Chung et al. 1997; Dumas et al. 1996)  and it has an anti-tyrosinase effect, inhibiting 
melanogenesis (Kameyama et al. 1996). 
 
In recent years, the actions of topically applied AA on human skin have been 
investigated in a limited number of in vivo studies. The ability of AA to protect against UV-
induced oxidative damage has been examined by Humbert et al. (2003) in a 6-month clinical 
trial. Specifically, these authors investigated the antiaging effect of topical AA on the sun-
exposed skin of the lower neck and forearm of 19 healthy female volunteers. A commercial 
cream containing 5 % AA was applied daily over a period of 6 months and was reported to 
lead to a statistically significant reduction in clinical signs of photo-ageing when compared 
with a placebo formulation.  
 
Nusgens et al. (2001) conducted a clinical study with 10 volunteers for 6 months to 
examine the effects of AA on collagen synthesis. A water-in-oil emulsion containing 5 % AA 
was applied once daily on the dorsal side of the upper forearm, while a control formulation 
with no AA was applied to the other side. Biopsies were taken from the treated sites and an 
increase of the mRNA of collagen type I and III as well as the mRNA of three extracellular 
procollagen processing enzymes was observed for the AA-treated sites compared with the 
control.  
 
Finally, Espinal-Perez et al. (2004) examined the depigmentation effect of topical 5 % AA on 
16 female patients’ facial skin with melasma over a 16-week period. The patients applied AA 
emulsion on one side of their face, and a 4 % hydroquinone emulsion on the other side of 
their face. Hydroquinone is a known bleaching agent for the skin (Jimbow et al. 1974) and 
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the researchers compared the pigmentary changes on the AA treated sites with those on the 
hydroquinone treated sites. Measurements of melanin index were taken at the beginning and 
at the end of the study, using a narrow-band reflectance spectrophotometer. AA showed 
similar lightening effect on the hyper-pigmented areas of the skin as hydroquinone. In a later 
study, Fitzpatrick and Rostan (2002) compared the clinical changes in 5 patients with 
moderate or severe dyspigmentation after daily application of a formulation containing 10 % 
AA and 7 % tetrahexyldecyl ascorbate for 12 weeks. However, these researchers reported no 
significant depigmentation on the AA treated sites when compared with the control. 
 
Chemically, AA is a dibasic acidic unsaturated lactone, which consists of an electron rich C2 
- C3 enediol moiety in a five-membered ring. This structure predisposes the molecule to 
oxidation and instability under either aerobic or anaerobic conditions. More specifically, the 
delocalization of π electrons in the molecule and the 2,3-enediol moiety conjugated with the 
C1 carbonyl group, make the proton on the C3 hydroxyl group significantly more acidic (pK1 
= 4.25) than the proton on the C2 hydroxyl group (pK2 = 11.57) (Benedini et al. 2011; Kibbe 
2009). The C2 - and C3 - OH groups are critical in electron donation and therefore oxidation 
of AA (Deutsch 1998; Finholt et al. 1965; Lavrenov and Preobrazhenskaya 2005). 
 
The rapid degradation of AA poses challenges for topical delivery of the molecule in 
cosmetic and pharmaceutical products. Moreover, the physicochemical properties of AA such 
as the melting point (190 – 192o C) partition coefficient (log P(o/w) = -1.85) and dissociation 
constant (pKa = 4.25) are not optimal for transport across skin. Attempts have been made to 
synthesise stable AA derivatives for topical delivery, including salts of l-ascorbyl 2-
phosphate or l-ascorbyl 6-palmitate (Austria, Semenzato, and Bettero 1997; Pinnell et al. 
2001). However, Austria and co-workers (1997) reported that the derivatives with a C6-OH 
esterified group, like l-ascorbyl 6-palmitate, did not show improved stability in aqueous 
solutions nor in topical formulations.  
 
3-O-ethyl-l-ascorbic acid (EA) is an l-ascorbic acid derivative with an ethyl group at the third 
carbon position. This structural modification protects the 3-OH group from ionization, and 
thus the molecule from oxidation, but also results in changes in the physicochemical 
properties. With regards to EA safety, to date, only two cases of allergic contact dermatitis 
have been reported in the literature. The first case was reported in 2014 (Yagami et al.), when 
a female patient developed an itchy erythematous rash after applying a 2 % EA lotion to the 
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face. Patch testing with the ingredients of the formulation indicated that EA was the causative 
allergen and showed the minimum positive concentration to be 0.05 % EA. One year later, a 
second case of allergic contact dermatitis due to EA were reported. A 51-year female was 
found to have an allergic reaction to EA after patch testing, with a minimum positive 
concentration of 1% EA (Numata et al. 2015). 
 
Even though EA is a compound widely used in topical products (Jeon et al. 2016; Silva et al. 
2019), surprisingly, its physicochemical properties have not been reported to date. 
Additionally, the skin permeation profile of EA has not been investigated nor have the effects 
of different vehicles on skin uptake of EA been examined. The objectives of the present work 
were therefore (i) to undertake a comprehensive characterisation of EA, (ii) to assess its 
solubility and stability in a range of solvents commonly used in topical preparations and (iii) 
to investigate skin delivery of EA from these solvents.  
 
 
 
 
2. Materials and methods  
 
2.1. Materials  
 
EA (Corum Inc., Taiwan) was a kind gift from Glaxo Smith Kline (GSK, U.K.). Propylene 
glycol (PG), 1-2 pentanediol (1-2P), 1-5 pentanediol (1-5P), 1-2 hexanediol (HEX), isopropyl 
alcohol (IPA), isopropyl myristate (IPM) and glycerol (GLY) were supplied by Sigma 
Aldrich, UK. Transcutol® (TC), Capryol 90® or propylene glycol monocaprylate (PGMC) 
Type II, Lauroglycol 90® or propylene glycol monolaurate (PGML) Type II and Labrafac® 
or medium chain triglycerides of caprylic (C8) and capric (C10) acids were a kind donation 
from Gattefossé (St. Priest, France). Dipropylene glycol (DiPG), tripropylene glycol (TriPG) 
and n-octanol (99% pure) were obtained from Acros Organics (UK). High Performance 
Liquid Chromatography (HPLC) grade water, methanol and ortho-phosphoric acid (H3PO4) 
were purchased from Fisher Scientific, UK. Phosphate-buffered saline (PBS) tablets were 
purchased from Oxoid Limited, UK. 
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2.2. Methods  
 
2.2.1. Thermal analysis  
 
The melting point of EA was examined using thermogravimetric analysis (TGA) and 
differential scanning calorimetry (DSC). TGA was performed using a Discovery TGA (TA 
Instruments, U.S.A.) system. The active was weighed in an open aluminium pan (TA 
Instruments, U.S.A.) and then heated inside the Discovery TGA furnace. The starting 
temperature and the final temperature were set to 25o C and 500o C, respectively, while the 
heating ramp was 10o C/min. A steady nitrogen flow of 25 ml/min was supplied throughout 
the analysis in order to create an inert atmosphere around the sample. A DSC Q2000 (TA 
Instruments, U.S. A.) system was used for the DSC analysis. The active was weighed in a 
hermetic aluminium pan (TA Instruments, U.S.A.) which was subsequently sealed with a 
hermetic aluminium lid (TA Instruments, U.S.A.) using a TzeroTM press (TA Instruments, 
U.S.A.). An empty hermetic aluminium pan (sealed with a hermetic aluminium lid) was used 
as a reference. Both the sample and reference were heated from 25o C to 220 o C, with a 
heating ramp of 10 o C/min and nitrogen flow of 50 ml/min.  
 
 
2.2.2. UV, NMR and mass spectra studies 
 
The UV spectra of EA at a concentration of 0.002 % w/v in HPLC water, methanol, an acidic 
aqueous solution and an alkaline aqueous solution were obtained using a Spectronic Bio 
MateTM 3 UV/VIS spectrophotometer (Thermo Scientific, U.S.A.).  The acidic medium was 
0.01 M HCl, pH = 2, and the basic medium was 0.01 M NaOH, pH = 12 (OECD 1981a). The 
UV absorption spectrum was acquired between 200 and 300 nm (step = 1 nm) in order to 
determine the optimum specific wavelength (λ) for analysis of the molecule.   
 
1H NMR and 13C NMR were collected using a Bruker AM500 spectrometer operating at 500 
MHz for proton and 126 MHz for carbon. Chemical shifts (δH and δC) are quoted as parts per 
million downfield from 0. The multiplicity of a 1H NMR signal is designated by one of the 
following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, br = broad and m = 
multiplet. High-resolution mass spectra were carried out using either a Kratos MS89MS with 
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Kratos DS90 software or a Jeol AX505W with Jeol complement data system. Samples were 
ionised electronically (EI), with an accelerating voltage of »6kV or by low resolution fast 
atom bombardment (FAB) in a thioglycerol matrix.   
 
 
2.2.3. pKa determination  
 
The dissociation constant of EA in water was determined according to OECD guidelines 
(1981b). Briefly, the UV absorption spectrum was obtained from solutions of fixed 
concentrations of EA (0.002 % w/v) at various pH values from 2 to 12. The absorbance of 
non-charged and the charged compound was measured with 0.01 N hydrochloric acid (HCl, 
pH = 2) and 0.01 N sodium hydroxide (NaOH, pH = 12) solutions, respectively. The UV 
absorption spectra for the dissociated and undissociated forms of EA were found to vary 
considerably at 275 nm, therefore UV absorption spectra were obtained at several 
intermediate pH values from 6.80 to 8.61. The various buffered solutions were prepared by 
adding equal volumes of a stock solution of EA in HPLC grade water to constant volumes of 
McIlvaine buffer solutions, prepared as described by Elving et al. (1956). The buffered 
solutions at pH 8.01 and 8.61 were prepared with boric acid and NaOH. The ionic strength 
was kept constant for all the solutions by adding potassium chloride (KCl) when needed. The 
pKa was calculated as described by Albert and Serjeant (1984). All pH measurements were 
taken using a symphony Dual Parameter pH metre (VWR International, U.K.) at room 
temperature.  
 
2.2.4. HPLC analysis and method validation  
 
The HPLC system consisted of a Hewlett-Packard (U.S.A.) series 1100 quaternary pump, an 
Agilent Technologies (U.S.A.) series 1100 auto sampler, a Hewlett-Packard (U.S.A.) series 
1100 system controller, an Agilent Technologies (U.S.A.) series 1100 degasser and an 
Agilent Technologies (U.S.A.) series 1100 UV detector. ChemStation® Rev. A.09.03 
(Agilent Technologies, U.S.A.) software was used to analyse the data. The HPLC system was 
equipped with a Luna® column, 250 x 4.60 mm, 5 μm, Phenyl-Hexyl (Phenomenex, U.K.) 
equipped with a universal HPLC guard column (Phenomenex, U.K.) packed with a 
SecurityGuard cartridge (Phenomenex, U.K.). The mobile phase consisted of methanol:water 
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[0.08%v/v orthophosphoric acid] (20:80). The UV detector was set to 242 nm, the flow rate 
to 1 ml/min and the column temperature to 30o C. The injection volume was 5 μl. The 
analytical method was validated for linearity, range, precision, accuracy, limit of detection, 
limit of quantitation, robustness and system suitability according to the International 
Conference on Harmonization guidelines (ICH 2005). 
 
A calibration curve ranging from 0.5 to 200 µg/ml was constructed to relate the concentration 
of the drug in solution to the peak area measurements obtained from the HPLC. A correlation 
coefficient value (r2) greater than 0.99 was obtained, which indicates an acceptable fit to the 
regression line (Shabir 2003). The retention time of EA was 7.62 ± 0.07 min. The accuracy, 
being the closeness of the measured value to the true value, was determined by preparing and 
injecting three different concentrations of EA and the findings were expressed as mean % 
recovery. A recovery of 99.51± 0.38% was achieved. Precision was assessed by 
determination of inter-day variability and intra-day repeatability. The % RSD values of 
intraday and inter-day precision were 0.13 % and 1.40 %, respectively.  The LOD value was 
0.10 µg/ml and the LOQ was 0.31 µg/ml. A sample HPLC chromatogram of EA detected in 
the receptor solution during a permeation experiment is shown in Fig. S1. 
 
2.2.5. Log P(o/w) determination 
 
The log P(o/w) value of EA was determined experimentally following the shake flask method 
according to the OECD guidelines (1995). Briefly, before the study, n-octanol and HPLC 
grade water were mutually saturated at the temperature of the experiment, 24 ± 1o C. A stock 
solution of EA at 0.0049 M (1 mg/ml) in water pre-saturated with n-octanol was prepared. In 
Eppendorf® tubes 2 ml, a stock solution of drug and the pre-saturated solvent were taken in 
the following ratios: 1: 1, 1: 0.5 and 0.5: 1. The tubes were then rotated through 180°C about 
their transverse axes (approximately 100-times for 5 min). Subsequently, the tubes were 
centrifuged at 24°C at 13,000 rpm for 20 min so that the two phases separated from each 
other. Samples were first taken from the n-octanol phase and diluted with ethanol. 
Subsequently, samples from the aqueous phase were collected, diluted and analysed by 
HPLC. All samples were prepared in duplicate.  
 
2.2.6. Solubility parameter, solubility and stability studies  
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The van Krevelen and Hoftyzer solubility parameters (δ) of the drug and solvents were 
calculated using Molecular Modeling Pro® software (Version 6.3.3, ChemSW, CA, USA). 
For solubility determinations, excess EA was added to each solvent in Eppendorf® tubes in 
triplicate. The tubes were capped and sealed with Parafilm® (Bemis Inc., U.S.A.) and placed 
in a shaking incubator for 48 h at 32 ± 1oC. Tubes were checked periodically to ensure an 
excess of the active remained in each tube. After 48 h each tube containing saturated mixtures 
was centrifuged for 15 min at 10,000 rpm and 32o C. The supernatant liquid was diluted with 
methanol in order to lie within the analytical range of the HPLC method.  
 
Stability of EA in the solvents was investigated for 120 h (5 d) at 32 ± 1o C. Solutions of 
known concentration of EA were prepared in triplicate and placed in an Eppendorf ® tube. 
The sample was sealed with Parafilm® (Bemis Inc., U.S.A.) and placed in a shaking 
incubator, as for solubility studies. Samples were collected at 0, 24, 48, 72, 96 and 120 h. All 
samples were subsequently diluted and analysed by HPLC.  
 
2.2.7. Finite dose permeation and mass balance studies 
 
EA solutions (2 % w/w) were prepared by placing a suitable amount of active ingredient in an 
Eppendorf ® tube containing a Teflon® coated magnetic stir bar. The permeation studies 
were conducted using vertical glass Franz-type diffusion cells and full thickness porcine ear 
skin according to procedures reported previously (Haque et al. 2017; OECD 2004). The 
diameter of both the donor and the receptor compartments of each Franz-cell were measured 
using an electronic digital micrometre (Fisher Scientific, U.K.). The experiments were 
conducted in a SUB 28 (Grant Instruments, U.K.) temperature-controlled water bath 
equipped with a Telesystem HP 15 (Variomag®, U.S.A.) submersible magnetic stirrer. 
Freshly prepared PBS (pH 7.3 ± 0.1) was used as the receptor solution. Once the skin 
temperature had equilibrated to 32 ± 1o C, 5 μl of the test solution were applied to the donor 
compartment which was not occluded. A volume of 200 μl of receptor solution was collected 
at 0, 15 min, 30 min, 1 h, 2 h, 5 h, 10 h, 12 h and 24 h, and equal volume of fresh temperature 
equilibrated PBS solution was added to the receptor compartment. All samples were analysed 
using HPLC. The number of replicate experiments was n  5. 
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At the end of the permeation studies, the receptor solution was removed from the Franz cells. 
A mass balance study was also conducted and validated. The skin surface was washed once 
with 1 ml of methanol and three times with 1 ml of water:methanol (50:50), followed by 
swabbing with a cotton bud. The Franz diffusion cells were disassembled, the skin 
membranes were cut into small pieces with scissors and placed in Eppendorf® tubes with 1 
ml of water: methanol (50:50). The skin samples were centrifuged for 1 min at 13,000 rpm at 
32o C and subsequently they were extracted by incubation for 5 h in an orbital shaker at 32o 
C. All samples were centrifuged at 13,000 rpm at 32o C for 20 min and the supernatant 
solution was analysed using HPLC.  
 
 
 
2.2.8. Data analysis 
 
The data was analysed in MS Excel® (Microsoft Corp., USA). Statistical significance was 
determined using one-way analysis of variance (ANOVA). Multiple comparisons between 
groups were performed by post hoc Tukey test. A probability of p < 0.05 was considered 
statistically significant. All results are presented as the mean ± SD. 
 
 
 
 
 
3. Results and discussion  
 
3.1. Thermal analysis 
One single endothermic peak was observed in the DSC curve at 114.39° C, with an 
extrapolating onset at 112.83° C and enthalpy of fusion 138.5 J/g (Fig. 1). Mass loss in the 
TGA was observed after 190° C (Fig. 2), a temperature above the melting observed in the 
DSC, indicating decomposition. This allowed identification of the pure compound, with no 
impurities or polymorphism evident. 
 
3.2. Ultraviolet, NMR and mass spectra 
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The UV maxima of EA in various solutions are shown in Table I. The NMR spectra are 
shown in Fig. 3-4.    
  
(±)-(2R)-2-[(1S)-1,2-dihydroxyethyl]-3-ethoxy-4-hydroxy-2H-furan-5-one. White powder; 
m.p. 114.39 °C; δ H (500 MHz; D2O) 1.35 (3H, t, CH3CH2OC[=C(OH)]CH), 3.69 – 3.76  
(2H, m, CH3CH2OC[=C(OH)]CH), 4.02 (1H, t, HOCH2CH(OH)C(H)OC=O), 4.55 (2H, d, 
HOCH2CH(OH)C(H)OC=O), 4.90 (1H, d, CH(OH)C(H)OC=O); δ H (500 MHz; DMSO-d6) 
1.27 (3H, t, CH3CH2OC[=C(OH)]CH), 3.37 – 3.47 (2H, m, CH3CH2OC[=C(OH)]CH), 3.60 – 
3.68 (1H, m, HOCH2CH(OH)C(H)OC=O), 4.34 – 4.48 (2H, m, HOCH2CH(OH)), 4.73 (1H, 
d, HOCH2C(H)OH), 4.84 (1H, t, HOCH2CH(OH)), 4.95 (1H, d, CH(OH)C(H)OC=O), 8.69 
(1H, s, C=C(OH)C=O); δ C (126 MHz; D2O) 14.53 (CH3CH2OC), 61.98 (CH3CH2OC), 
68.35 (HOCH2CH(OH)C), 68.93 (HOCH2CH(OH)C), 76.12 C(H)OC=O, 117.76 
(O=CC(OH)=C), 154.52 (HOC=C(OCH2CH3), 173.58 (C=O); δ C (126 MHz; DMSO-d6) 
15.31 (CH3CH2OC), 61.76 (CH3CH2OC), 66.56 (HOCH2CH(OH)C), 68.49 
(HOCH2CH(OH)C), 74.43 C(H)OC=O, 118.84 (O=CC(OH)=C), 150.55 
(HOC=C(OCH2CH3), 170.62 (C=O); m/z 205 (100%, [M+H]
+): Found [M+H]+ 205.0710, 
C8H12O6 requires 205.0712. Consistent with previous report (MSDS 2012). 
 
3.3. pKa and log P(o/w) determination 
 
The pKa value was calculated as described by Albert and Serjeant (1984), according to the 
equations pKa = 𝐻 + log
𝐴𝐼−𝐴
𝐴−𝐴𝑀
 , where AI is the absorbance of the ionised species and AM the 
absorbance of the molecular species. EA was found to have a pKa of 7.72 ± 0.01 at room 
temperature. The log P(o/w) of EA was experimentally found to be -1.07 ± 0.03.  
 
3.4. Solubility of EA in candidate solvents  
 
The saturation solubility values of EA in the solvents studied are shown in Fig. 5. The 
calculated solubility parameters of vehicles are also shown. The solubility parameter of EA 
was calculated as 15.4 ((cal/cm3)1/2). EA solubility ranged from 463.6 ± 1.3 mg/ml to 801.1 ± 
1.7 mg/ml for the hydrophilic solvents. Lower solubility was found for the lipophilic solvents 
Lab, IPM, PGML and PGMC, ranging from 0.6 ± 0.2 mg/ml to 56.6 ± 1.3 mg/ml. Of all the 
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vehicles examined, EA was found to be less stable in TriPG and DiPG after 120 h, with 
recovery values of 76.64 and 82.76 % respectively. In all other solvents, recovery of EA 
ranged from 90.23 % to 101.51 %, as shown in Fig. S2. 
 
The solvents were selected based on the hypothesis that solvents with low solubility 
parameters (δ) could enhance the permeation of the active. This would be expected because 
of the subsequent low saturation solubility and therefore the high thermodynamic activity of 
EA in these solvents. Additionally, it has been reported that when the solubility parameter of 
the vehicle is similar to that of skin, that is 10 (cal/cm3)1/2 (Liron and Cohen 1984), then the 
active will have increased affinity for the membrane and thus, it will be well taken up by this 
membrane (Dias, Hadgraft, and Lane 2007; Mohammed et al. 2014). Therefore, the solubility 
parameter, which is defined as the sum of the cohesive forces of the molecule, is one of the 
values taken into account when choosing the vehicle (Hansen 2007). Finally, hydrophilic 
solvents with solubility parameter values (δ) close to those of the active, are expected to 
promote permeation by shifting the δ values of the skin towards the δ value of the EA (15.4 
(cal/cm3)1/2), thereby increasing the solubility and partitioning of the active inside the 
membrane (Lane 2013; Liron and Cohen 1984).  
 
3.5. Permeation Studies 
 
Finite dose permeation studies of EA were performed using GLY, PG, HEX, 1-2P, 1-5P, 
IPA, DiPG, TriPG, TC, PGMC and PGML. All permeation studies were conducted for 24 h 
with samples (200 μl) taken at different time points (t = 0, 15 min, 30 min, 1h, 2h, 5h, 8h, 
10h, 12h and 24h). A dose of 5 μl/cm2 of 2 % w/w EA formulation was applied on the 
surface of the skin. The selection of solvents covered a range of solubility parameter values 
from 17.1 to 9.4 (cal/cm3)1/2, with GLY being the most hydrophilic and PGML the most 
hydrophobic as previously shown in Fig 3. Permeation of EA was evident for GLY, PG, 1-
2P, HEX, IPA, PGMC and PGML, as shown in Fig. 6. The highest amount of EA that 
permeated at 24 h was from PG (7.54 ± 3.22 μg/cm2), followed by GLY (6.49 ± 4.89 μg/cm2) 
and HEX (5.23 ± 2.11 μg/cm2); however, the values were not significantly different from 
each other (p > 0.05).  
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PG, 1-2P and HEX are hydrophilic low molecular weight 1,2 glycols that have been used in 
personal care products as solvents, skin and hair conditioning agents and viscosity increasing 
agents (Johnson et al. 2012). With regards to HEX, the ability of this glycol to promote skin 
permeation has not been investigated in human skin to date. This is the first study to assess 
the permeation enhancing properties of HEX using pig skin.  
 
PG has been used for many years as a penetration enhancer for a number of compounds, 
however the mechanism of action has not been elucidated. It is considered that PG may act 
by increasing the partition or solubility of a drug in the stratum corneum (Lane 2013). 
Pudney et al. (2007) and Mohammed et al. (2014) used Confocal Raman spectroscopy to 
monitor the fate of vehicles and the actives as they permeate in humans in vivo. They found 
that the penetration of trans-retinol and niacinamide respectively was highly correlated with 
the depth of penetration of the PG. Brinkmann and Müller-Goymann (2005) used DSC, 
WAXD and SAXD to examine the effects of PG on human stratum corneum. They proposed 
that the molecule integrates into hydrophilic regions of hexagonally ordered lipids, thereby 
increasing the distance of the lipids and resulting in higher flux. 
 
The exact mechanism of action of 1-2P as a skin penetration enhancer is not clear, it has been 
shown to promote increased delivery of a number of compounds. Duracher et al. (2009) 
found that 1-2P enhanced the permeation of caffeine in porcine skin and Heuschkel et al. 
(2008) showed that mixtures of 1-2P with 1-2 butanediol resulted in enhanced permeation of 
dihydrovenavenanthramide D across full thickness human skin. Recently, Steiner and co-
workers (2017) examined the fate of 1-2P when applied to pig skin; 1-2P evaporated rapidly 
and only a quarter of the initial dose could be recovered after 24 h. Therefore, 1-2P can 
increase the thermodynamic activity of the active over time. In the present work single 
solvent systems of 1-2P did result in permeation of EA (2.01 ± 1.27 μg/cm2). However, as 
shown in Fig. 6, both PG and HEX delivered significantly higher cumulative amounts of EA 
than 1-2P (p < 0.05).  
 
The solvent GLY is used in cosmetics as a humectant and skin-conditioning agent. The effect 
of GLY on the stratum corneum hydration has been proposed to result in a penetration 
enhancing effect. Bettinger et al. (1998) reported enhanced permeation of hexyl nicotinate 
acid in vivo in glycerol-treated sites of human subjects. This phenomenon was attributed to 
the interactions of glycerol with the stratum corneum lipids, enhanced desmosomal 
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degradation, and the hydrating effect of glycerol. Brinkmann and Müller-Goymann (2005) 
investigated the effects of various solvents on human stratum corneum by DSC, WAXD and 
SAXD and they proposed that GLY intercalates between the hydrophilic heads of the 
orthorhombically packed lipids of the stratum corneum. This resulted in an increase of the 
gaps in the lipid bilayers, altering the stratum corneum barrier in a similar manner as PG.  
Regarding the influence of the lipophilic solvents, permeation of EA for PGML (3.76 ± 0.54 
μg/cm2) was significantly higher than PGMC (2.59 ± 0.96 μg/cm2, p < 0.05). The ability of 
PGML to act as a skin penetration enhancer has been reported previously (Haque et al. 2017; 
Hirata et al. 2013; Mohammed et al. 2014). Parisi et al. (2016) suggested that the presence of 
unesterified lauric acid in PGML may contribute to the enhancing effect of the solvent on the 
permeation of the active.  All solvents delivered significantly higher amounts of EA 
comparing to IPA (0.45 ± 0.55 μg/cm2, p < 0.01). For the solvents PG, GLY, HEX, 
permeation of EA was detected after 5 h; however, permeation of EA for 1-2P, PGML, 
PGMC and IPA was not detected until 12 h (Fig. 6). 
 
The results for mass balance studies and percentage permeation of applied EA are shown in 
table II. In general, the percentage permeation values of EA for the solvents follow the same 
order as the cumulative amounts permeated.  The percentage permeations for the PG, HEX 
and GLY were similar, being 7.14, 6.06 and 5.39 % respectively. However, the percentage 
EA permeation for 1-2P (2.01 %) was significantly lower than PG and HEX (p < 0.05). For 
the hydrophobic solvents, the percentage EA permeation at 24 h for PGML (5.58 %) is 
significantly higher than PGMC (3.93 %, p < 0.05). All solvents resulted in higher percentage 
permeation comparing to IPA (0.60 %, p < 0.05). This may reflect the rapid evaporation of 
IPA compared to the other vehicles. 
 
The percentage skin retention of applied EA was similar for HEX, PG, IPA and PGMC, 
ranging from 18.55 to 20.94 % (p > 0.05). Compared with these solvents, the percentage 
retention of EA was significantly lower for GLY (8.84 %, p < 0.05). The solvents HEX, PG, 
IPA and PGMC resulted in higher percentage retention of EA compared with 1-2P (10.18 %, 
p < 0.05). The solvents TC, DiPG and PGML deposited comparable percentages of EA, 
namely 12.01, 13.92 and 15.93 % respectively and these values were not different than HEX, 
PG, IPA and PGMC (p > 0.05). TC and IPA are hydrophilic solvents that both have 
previously been reported to increase the permeation and retention of various drugs across the 
skin (Brinkmann and Müller-Goymann 2005; Chadha et al. 2011; Harrison et al. 1996; 
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Oliveira, Hadgraft, and Lane 2012). Haque et al. (2017) showed that skin penetration of 
anthramycin correlated with permeation of the vehicles. TC permeated rapidly through 
human skin, resulting in a plateau of drug permeation in the absence of the solvent. 
Considering the high retention of EA inside the skin together with the negligible permeation 
for either TC or IPA, it is likely that the rapid evaporation of the solvents may have resulted, 
similarly, in deposition of EA in the skin. A significantly higher percentage of EA retention 
was observed for PGMC (20.94 %) compared with PGML (15.93 %, p < 0.05).  
 
1-5P has been reported to have antimicrobial and antifungal properties in pharmaceutical 
applications and it can be used as a moisturizing substance and solvent. Penetration 
enhancement tests in vitro showed 1-5P to be a penetration enhancer for certain 
pharmaceutical drugs in human skin, such as terbinafine (Evenbratt and Faergemann 2009) 
and triiodothyroacetic acid (Faergemann et al. 2005). However, Møllgaard and Hoelgaard 
(1983) proposed that 1-5P has no effect on the barrier function and showed that compared 
with other diols, 1-5P delivered the lowest amount of estradiol across human skin. Here, we 
found no penetration of EA when we used neat 1-5P as solvent (Table II). The solvents DiPG 
and TriPG are hydrophilic oligomers of PG with low molecular weights that are used as 
solvents, viscosity decreasing agents, and humectants (Fiume et al. 2012). Haque et al. (2017) 
showed that the percentage permeation of DiPG in human skin after finite dosing was 2.6 % 
at 24 h. Fasano et al. (2011) used human skin to validate a mathematical model for estimation 
of permeation and predicted that the amount of TriPG penetrating the skin is expected to be 
2-fold lower than DiPG. The low amounts of penetration observed here may reflect the 
limited permeation of these solvents through the skin. Haque et al. (2017) showed that when 
DiPG was used as a vehicle for anthramycin, it resulted in no permeation of the drug across 
the skin membrane. The total recovery after mass balance ideally should be 100 ± 15% 
(SCCS 2010). The total recovery of the active for PG, GLY, HEX, PGML and 1,2P was 
74.86 %, 67.05 %, 56.51 %, 77.98 % and 97.74 % respectively. Total recovery of EA was 
lower than the recommended values, reflecting partial degradation of EA inside the skin. 
Studies are ongoing with human skin equivalent tissues in order to elucidate the breakdown 
of EA. 
 
4. Conclusions 
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EA has been used in cosmetic products as a stable alternative to AA for a number of years. 
Additionally, EA containing products have been used for skin whitening and topical EA has 
been reported to be effective in treating medical conditions of hyper-pigmentation, such as 
melasma. Finally, because of its reducing ability, EA should be investigated as an antioxidant 
ingredient to increase stability of pharmaceutical formulations. To our knowledge this is the 
first report that characterizes the physicochemical properties of the molecule. This study is 
the first to report in vitro permeation and skin uptake data from a number of neat solvents 
under finite dosing. Among the hydrophilic solvents, PG, GLY and HEX delivered higher 
amounts of EA through the skin compared with the other vehicles, while for the lipophilic 
solvents. PGML resulted in significantly higher cumulative permeation of EA than PGMC. 
Knowledge of the physicochemical properties of EA, as well as the effect of single solvents 
will enable a selection of the most appropriate solvents for future formulation development of 
EA as well as of other molecules with similar physicochemical properties. Development of 
binary, ternary and more complex solvent systems that synergistically enhance penetration of 
the molecule will be the subject of a future publication. The stability of EA warrants further 
investigation, given some of the low recovery values observed. The identification and 
substantial quantification of the EA degradants should allow a greater understanding of the 
fate of EA inside the skin and will be also be the subject of future work.  
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Figure 1 – DSC analysis of 3-o-ethyl-l-ascorbic acid 
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 Figure 2 – TGA analysis of 3-o-ethyl-l-ascorbic acid 
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Figure 3 – 1H NMR spectrum of 3-o-ethyl-l-ascorbic acid in D2O. 
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Figure 4 – 13C NMR spectrum of 3-o-ethyl-l-ascorbic acid in D2O. 
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Figure 5 – Solubility parameter values of various solvents plotted against saturation solubility of 3-O-
ethyl-l-ascorbic acid in vehicles at 32 ± 1 °C, n ≥ 3, mean ± SD. 
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Figure 6 – Cumulative permeation of 3-O-ethyl-l-ascorbic acid over time for single solvent systems (n ≥ 5, 
mean ± SD, *p < 0.05). 
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Table I – UV maxima of EA in various solutions 
 λmax (nm) 
Distilled water 242-243 
Acidic solution (HCl 0.01N) 242 
Alkaline solution (NaOH 0.01N) 275 
Methanol 241-242 
 
Table II – Cumulative permeation and percentage (%) permeation, skin extraction, 
recovery from skin surface and total recovery of EA for neat solvents (mean ± SD, n 
≥ 5). 
Solvent Cumulative permeation 
(µg/cm2) 
Percentage (%) of applied dose 
% extraction % permeation % washed from the 
surface 
% total recovery 
GLY 6.49 ± 4.89 8.84 ± 6.74 5.39 ± 4.04 52.78 ± 29.18 69.34 ± 18.94 
PG 7.54 ± 3.22 19.45 ± 5.98 7.47 ± 3.05 42.07 ± 14.01 72.92 ± 16.65 
1-2P 2.01 ± 1.27 10.18 ± 2.90 2.01 ± 1.29 82.15 ± 11.03 94.34 ± 7.94 
HEX 5.23 ± 2.11 18.55 ± 3.09 6.07 ± 2.36 25.25 ± 10.47 56.51 ± 10.78 
TC 0.00 ± 0.00 12.01 ± 8.46 0.00 ± 0.00 45.92 ± 7.58 65.16 ± 6.27 
IPA 0.46 ± 0.55 20.30 ± 6.57 0.60 ± 0.71 40.89 ± 9.05 61.79 ± 10.50 
1-5P 0.00 ± 0.00 0.21 ± 0.41 0.00 ± 0.00 85.72 ± 32.47 87.72 ± 29.57 
PGML 3.76 ± 0.54 15.93 ± 2.69 5.58 ± 0.79 51.89 ± 13.30 73.41 ± 11.99 
PGMC 2.59 ± 0.96 20.94 ± 4.25 3.93 ± 1.42 74.68 ± 10.29 99.55 ± 8.64 
DiPG 0.00 ± 0.00 13.92 ± 17.03 0.00 ± 0.00 72.41 ± 14.79 86.79 ± 13.21 
TriPG 0.00 ± 0.00 0.70 ± 0.67 0.00 ± 0.00 97.43 ± 5. 73 101.87 ± 5.25 
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